This company has been marked as potentially delisted and may not be actively trading. NYSE:AGE AgeX Therapeutics (AGE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About AgeX Therapeutics Stock (NYSE:AGE) 30 days 90 days 365 days Advanced Chart Get AgeX Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.22▼$16.5152-Week Range N/AVolume3,700 shsAverage Volume3,849 shsMarket Capitalization$11.99 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California. Read More Receive AGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AgeX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AGE Stock News HeadlinesHC Wainwright & Co. Initiates Coverage of Serina Therapeutics (SER) with Buy RecommendationJuly 14, 2025 | msn.comJones Trading Initiates Coverage of Serina Therapeutics (SER) with Buy RecommendationMarch 12, 2025 | msn.comSQ exploded after this hidden signal appearedThe current market uncertainty shouldn't completely scare you. I won't deny the anxiety from turning on the news to see reports of yet another tariff, another hike, another loss and another plunge… But uncertain environments like these are where I look to find a very specific trading opportunity. That's because in a volatile market, stocks make unusually high momentum moves in either direction – and that's exactly what I look to front-run. From the looks of things, we still have a few more weeks of high uncertainty. Which is why I'll be leveraging a special type of setup built to thrive in these conditions…August 22 at 2:00 AM | Wealthpin Pro (Ad)Serina Therapeutics initiated with a Buy at JonesResearchMarch 10, 2025 | markets.businessinsider.comSerina Therapeutics sells UniverXome subsidiaryJanuary 17, 2025 | markets.businessinsider.comSerina Therapeutics Inc (SER)November 7, 2024 | investing.comGlobal Clinical Laboratory Service Market to Cross ~USD 400 Billion Mark by 2030 | DelveInsightOctober 17, 2024 | finance.yahoo.comSerina Therapeutics to Present at the 14th Annual Injectables SummitOctober 2, 2024 | markets.businessinsider.comSee More Headlines AGE Stock Analysis - Frequently Asked Questions When did AgeX Therapeutics' stock split? AgeX Therapeutics's stock split on Monday, March 18th 2024.The 8-5 split was announced on Monday, March 18th 2024. The newly created shares were distributed to shareholders after the closing bell on Monday, March 18th 2024. An investor that had 100 shares of stock prior to the split would have 160 shares after the split. What other stocks do shareholders of AgeX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that AgeX Therapeutics investors own include Allena Pharmaceuticals (ALNA), Biocept (BIOC), Aadi Bioscience (AADI), Arbutus Biopharma (ABUS) and Adamis Pharmaceuticals (ADMP). Company Calendar Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:AGE CIK1708599 Webwww.agexinc.com Phone(510) 671-8370Fax510-871-4154Employees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)($13.0282) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.80 million Net Margins-10,424.65% Pretax Margin-10,430.28% Return on EquityN/A Return on Assets-120.90% Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.36 Sales & Book Value Annual Sales$140 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($16.07) per share Price / BookN/AMiscellaneous Outstanding Shares1,080,000Free Float1,008,000Market Cap$11.99 million OptionableNot Optionable Beta1.18 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NYSE:AGE) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AgeX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AgeX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.